FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Real-time Bid/Ask 03:03:08 20/05/2024 pm IST | ||
| 3.7 EUR / 3.71 EUR | +3.49% |
|
| Current month | -0.56% | ||
| 1 month | -54.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 3.58 | +2.29% |
| 16/24/16 | 3.5 | +1.74% |
| 15/24/15 | 3.44 | +3.93% |
| 14/24/14 | 3.31 | +2.48% |
| 13/24/13 | 3.23 | +2.54% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 05:49 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG0WAJ |
| ISIN | DE000MG0WAJ2 |
| Date issued | 25/03/2024 |
| Strike | 14,129 p |
| Maturity | Unlimited |
| Parity | 6.55 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.92 € |
|---|---|
| Lowest since issue | 3.08 € |
| Spread | 0.01 € |
| Spread % | 0.27% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.9
USD
Spread / Average Target
+9.10%
- Stock Market
- Certificates
- Certificat
